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Purpose of the study
Liver steatosis is a common and important histological
finding in hepatitis C, and is associated with an increased
progression of the disease. In HIV co-infected patients,
steatosis was independently associated with d-drugs, such
as stavudine, especially in non-3 HCV genotypes. We
investigate the safety of tenofovir disoproxil fumarate
(TDF) in determining hepatic steatosis in HIV/HCV co-
infected patients.
Methods
All consecutive HCV-infected patients who had under-
gone a liver biopsy have been included in this study. Pri-
mary outcomes were the presence or absence of steatosis,
or the presence of fibrosis.
Summary of results
370 HCV-infected patients underwent liver biopsy; 182
co-infected with HIV. Steatosis (>5% in liver biopsy) was
diagnosed in 33.0% of HCV mono-infected and in 47.3%
in HIV co-infected patients (OR 1.82; p = 0.005). Fifty HIV
patients (27.5%) were naïve to antiretroviral therapy.
Eighty-nine patients received stavudine for a median of 38
months (IQR 17.5–58), while 36 patients received tenofo-
vir for a median of 23 months (IQR 8.8–32). Factors asso-
ciated with steatosis were: genotype 3 (OR 3,14; p <
0.001), presence of fibrosis (OR 1.91; p = 0.039), dura-
tion of HCV infection (OR 1.10; p = 0.001) and use of d4T
in HIV patients (OR 3.00; p = 0.021). Considering only
patients with genotype 3, duration of HCV infection (OR
1.19; p = 0.001) and HCV RNA levels (OR. 1.04; p =
0.039) were the only determinants of steatosis. In HCV
genotype other than 3 the risk of steatosis was related to
fibrosis (OR 3.95; p = 0.002), use of d4T (OR 4.98; p =
0.014) and older age (OR 1.09; p = 0.014). In all cases use
of TDF was not associated with steatosis.
Conclusion
As previously described, the risk of steatosis is mainly
associated to HCV genotype 3 in patients infected by
HCV. HIV co-infected patients with genotype other than 3
are at risk of developing steatosis with stavudine but not
with tenofovir.
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